Futura Medical Raises Revenue Outlook Amid Strategic Review, Bolstered by Eroxon Momentum
UK-based Futura Medical has upgraded its full-year revenue forecast to £1.7 million for 2025, citing strong performance of its over-the-counter erectile dysfunction gel Eroxon. The announcement comes as the company prepares for a strategic review and anticipates key financial catalysts, including a milestone payment from partner Haleon.